Isomorphic Labs Deep Dive 2026: $2.7B Raised, Eyeing $50B

As of November 12, 2026, Isomorphic Labs has raised $2.7 billion from outside investors and, per Bloomberg, is in talks to raise about $5 billion more at a valuation near $50 billion — while its UK operating company reported zero turnover for 2025 and no drug it designed has entered a human trial.

Isomorphic Labs is the drug discovery company Demis Hassabis carved out of Google DeepMind to turn AlphaFold's protein-structure breakthroughs into medicines. It is still owned by Alphabet, yet it is now priced by outside investors like a large-cap pharma company. This deep dive covers what Isomorphic actually builds, how its partnership model pays, the full funding record, what its filed accounts show, the IsoDDE engine, the competitive field, leadership, and what is and isn't known about a spinout or IPO.

Isomorphic Labs Company Snapshot

Isomorphic Labs is a London-based, Alphabet-owned AI drug design company founded in 2021 that has raised $2.7 billion in two external rounds, both led by Thrive Capital, and has three pharma partners: Eli Lilly, Novartis and Johnson & Johnson. Its UK operating company lost £159.4 million in 2025 with an average of 225 employees.

Funding from Isomorphic Labs' own announcements; valuation talks per Bloomberg as reported by The Next Web; loss and headcount from the 2025 accounts of Isomorphic Labs Limited filed at Companies House on October 2, 2026.

What Isomorphic Labs Actually Does

Isomorphic Labs designs drug candidates on a computer before anyone synthesizes them in a lab. Alphabet announced the spinout on November 4, 2021 as a for-profit company separate from DeepMind and its third major life-sciences bet after Verily and Calico, with Hassabis leading it while keeping his DeepMind job. The premise came straight from AlphaFold, the DeepMind system that predicts a protein's 3D shape in minutes to hours, work that earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry.

A protein's shape tells chemists where a drug might bind. Isomorphic's job is the harder next step: predicting which molecule binds that pocket, how tightly, and whether it can be made into a safe medicine. The company says it runs its own programs mainly in oncology and immunology and also designs molecules against targets chosen by its pharma partners, across small molecules, antibodies, peptides and molecular glues.

How Does Isomorphic Labs Make Money?

Isomorphic Labs makes money today only through pharma partnership payments, and its filed UK accounts book those as other operating income, not turnover. The directors' report describes the deals as Multi Target Research Collaboration and License Agreements paid through upfront fees, milestone payments and tiered royalties on future drug sales.

The Lilly and Novartis terms were reported by SiliconANGLE on January 7, 2024 at about $3 billion combined, but that headline is a ceiling: $82.5 million was paid upfront, and the rest depends on milestones. Eli Lilly's deal is the larger of the two by milestone value. The Novartis expansion and the Johnson & Johnson collaboration are on Isomorphic's own newsroom.

How Much Has Isomorphic Labs Raised? Funding History

Isomorphic Labs was funded only by Alphabet until March 31, 2025, when it raised $600 million in its first external round, led by Thrive Capital with GV and Alphabet. Fourteen months later it closed a $2.1 billion Series B, again led by Thrive, with Alphabet and GV returning and MGX, Temasek, CapitalG and the UK Sovereign AI Fund joining. Neither round disclosed a valuation.

How we counted: external rounds from Isomorphic Labs' announcements; Alphabet-side capital from Isomorphic Labs Limited's Companies House filings; talks from Bloomberg as reported by Tech Funding News and The Next Web; 2021 to November 2026; 7 events; as of November 12, 2026. Sterling rows are transfers from the parent into the UK operating company and may include proceeds of the external rounds, so they should not be added to the dollar rounds.

Isomorphic Labs' price tag moved fast after the Series B. Bloomberg reported on October 8, 2026 that the company was in early talks at a valuation of at least $40 billion, according to Tech Funding News, and then on November 4 that it was discussing about $5 billion at roughly $50 billion; The Next Web reported that the financing had not closed and terms could change. No lead investor has been named.

Product Portfolio

IsoDDE: The Engine Behind the $50B Pitch

Isomorphic Labs' IsoDDE is the asset investors are actually pricing, because the company has no product revenue and no clinical data. In a February 10, 2026 technical report, Isomorphic claimed IsoDDE doubles AlphaFold 3's accuracy on protein-ligand structures that differ sharply from its training data, finds previously unknown binding pockets from a protein's sequence alone within seconds, and predicts binding strength at a fraction of the time and cost of physics-based methods. President Max Jaderberg wrote in September 2026 that the engine can search for new molecules on a computer in days.

The catch is that the report is the company's own. It disclosed benchmark results but little about the model architecture or training data, and Schrödinger's CEO publicly criticized it for lacking the detail needed to check the conclusions. Isomorphic has also said the versions it uses internally differ from the one benchmarked, which makes outside replication harder still.

One read on this: Isomorphic has chosen to keep IsoDDE closed and monetize it through drug ownership and partner milestones rather than licensing it as a tool. That keeps the upside in-house if the molecules work, but it means the valuation rests on a model only Isomorphic and its partners can test.

Revenue and Key Metrics

Isomorphic Labs Limited, the UK operating company, reported no turnover in 2025 or 2024, according to its EY-audited 2025 accounts filed at Companies House on October 2, 2026. It recognized £55.2 million of other operating income from its partnership agreements in 2025, up from £19.1 million in 2024, and the directors wrote that the company "has not yet achieved any such milestones."

Administration expenses, which the filing says are mainly staff and research costs, rose from £113.4 million to £250.7 million, and average headcount rose from 125 to 225. Bloomberg put staff at more than 350 by May 2026. The accounts also show a £19.0 million UK tax credit and £17.2 million of interest income in 2025. These figures cover the UK company only; the filing states it had no branches outside the United Kingdom, so the Cambridge, Massachusetts and Lausanne teams may sit in other group entities.

Who Are Isomorphic Labs' Competitors?

Isomorphic Labs competes for pharma partnerships and AI talent with venture-backed drug design startups, chiefly Chai Discovery, which raised a $400 million Series C at a $3.8 billion valuation in July 2026 (see our Chai Discovery breakdown), and Xaira Therapeutics, which launched in April 2024 with more than $1 billion from ARCH Venture Partners and Foresite Capital. Our wider AI drug discovery startups roundup covers the rest of the field.

How we counted: each company's latest disclosed round as reported by Tech Funding News (October 2026) and company announcements; 3 companies; as of November 12, 2026.

Isomorphic's ~$50B is a reported target for a round that has not closed; Chai's $3.8B is a closed Series C price. A $50B mark would be about 13x Chai's (Value Add VC arithmetic).

Isomorphic Labs also faces competition from the frontier AI labs. Novo Nordisk said in April 2026 that it was partnering with OpenAI to find drug candidates, The Daily Upside noted, and Sanofi had already teamed with OpenAI and Formation Bio. Big pharma can now buy AI design capacity from more than one source.

Leadership Team

Bull Case / Bear Case

What the headline misses

Isomorphic Labs' $2.7 billion external total excludes years of Alphabet funding that was never announced as a dollar round, so the company's true lifetime capital is higher. The Companies House figures cover only the UK operating company, and the "not yet in human trials" status could change quickly: Hassabis's stated goal is a first trial by the end of 2026.

Will Isomorphic Labs IPO? IPO Outlook

Isomorphic Labs has no announced IPO plan as of November 12, 2026: no filing, no reported bank mandate and no target date. The strongest signal is Hassabis's comment to Bloomberg News after the May 2026 Series B that a full spinoff from Alphabet is "definitely" possible, as reported by The Daily Upside. A full spinoff is a precondition for a standalone listing, not the same thing as one.

The clinical timeline matters more than the capital markets for now. Hassabis told the World Economic Forum in Davos in January 2026 that he expected Isomorphic's first clinical trials by the end of the year, Reuters reported, a year later than his earlier end-2025 target. At the Bloomberg Tech conference in London in early November, Jaderberg said the work is still preclinical and that the company is in its "first innings." Drug companies usually list with clinical data in hand, so the realistic sequence is first trial, then a larger private round, then any public listing. That sequence is our analysis, not company guidance.